← Back to all trials
Recruiting
NCT07885475
Dexmedetomidine for Refractory Pain in Palliative Cancer Patients
Conditions: Cancer, Palliative Care, Patient Care, Pain Management, Dexmedetomidine Analgesia, Opioid
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 30
Sponsor: St. Olavs Hospital
Location: Drammen Hospital Drammen
Summary
The goal of this study is to find out whether the medication dexmedetomidine can be a safe and effective additional treatment for cancer patients whose pain is not well controlled by standard pain medicines (such as opioids).
The study includes 30 palliative care patients who still have significant pain despite standard pain treatment. All participants will receive dexmedetomidine, and outcomes related to efficacy and safety will be systematically observed.
Eligibility Criteria
Inclusion Criteria:
* Adult cancer patients (\>18 years), not receiving curative treatment
* Treated with parenteral opioids for cancer-related pain
* Indication to start dexmedetomidine treatment due to uncontrolled background pain (NRS \> 4 in a numeric rating scale (NRS 0-10)) despite hospitalization and standard pain management.
Exclusion Criteria:
* Dexmedetomidine hypersensitivity
* Hypotension (systolic blood pressure (BP) \< 90)
* Bradycardia (heart rate (HR) \< 50)
* Serious heart disease or AV block grade 2 or 3 if no pacemaker.
* Severe liver failure (e.g. Child-Pugh-C or similar)
* Acute cerebrovascular disease
* Neuraxial pain management
* Patients unable to comply with trial procedures
Source: ClinicalTrials.gov (NCT07885475). StuddyBuddy aggregates publicly available trial information.
